Ibrutinib inhibits the replication of multiple poxviruses by targeting the Bruton tyrosine kinase
ABSTRACT The recent surge in global monkeypox (mpox) outbreaks highlights the critical need for developing antiviral agents targeting orthopoxvirus infections. Ibrutinib, a selective Bruton tyrosine kinase (BTK) inhibitor initially approved by the FDA in 2013 for treating chronic lymphocytic leukemi...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
American Society for Microbiology
2025-09-01
|
| Ráidu: | Journal of Virology |
| Fáttát: | |
| Liŋkkat: | https://journals.asm.org/doi/10.1128/jvi.00517-25 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|